Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 25;7:119. doi: 10.1186/s40478-019-0774-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Effectiveness of dabrafenib and trametinib against BRAF V600E-mutant GBM cell lines in vitro. Targeted treatment reduced the viability of NGT41 and other BRAF V600E-mutant glioma cell lines (AM38, DBTRG-05MG) relative to BRAF-wildtype glioma cell lines (U87MG, T98G). (n ≧6, ^*p < 0.05, ^**p < 0.01, ^†p < 0.001, ^‡p < 0.0001; Two-way ANOVA) (a). Marked inhibition of phosphorylated MEK and ERK was observed in BRAF V600E-mutant cell lines. The expression of phosphorylated ERK was suppressed by trametinib treatment, regardless of BRAF status (b)